FVIII, the blood clotting protein missing in hemophilia A, adopts multiple shapes, making it more likely to be targeted by ...

The Hemophilia B treatment landscape is entering a new era, marked by disruptive innovation, curative potential, and renewed global attention. Once viewed as a lifelong burden requiring constant ...

Researchers from the Centenary Institute have uncovered a reason why some people with hemophilia A develop resistance to ...

Genentech’s short film draws on the experiences of multiple families caring for children with hemophilia A, seeking to ...

Cell and gene therapies harbor great hopes for biomedicine. They are becoming increasingly important for diseases that are ...

MHH haematologists successfully treat seriously ill patients with acquired haemophilia A with CAR-T cells.

Asia Pacific’s Market Growth: The Asia Pacific region is anticipated to experience significant growth in the bleeding disorder testing market, with a projected CAGR of 6.5% from 2023 to 2033. This is ...

Hemophilia A and B coagulation defects, which are caused by deficiencies of Factor VIII and Factor IX, respectively, can be bypassed by administration of recombinant Factor VIIa. However, the ...

Patients diagnosed with acquired (autoimmune) hemophilia, a serious and rare bleeding disorder, have high rates of hospital ...

VIJAYAWADA: The State government is committed to ensuring uninterrupted care for citizens with rare and chronic disorders ...

Treatment options for children with hemophilia A have expanded with the FDA approval of Bayer's Jivi antihemophilic factor (recombinant), PEGylated-aucl for the treatment of pediatric patients between ...

Minister emphasizes raising awareness about genetic disorders like thalassemia, sickle cell anemia, and hemophilia for timely ...